Prevalence of Clinical Cardiovascular Disease Risk Factors Among HIV Infected Patients on Anti-Retroviral Treatment in a Tertiary Hospital in Ethiopia.

IF 1.5 Q4 INFECTIOUS DISEASES
HIV AIDS-Research and Palliative Care Pub Date : 2022-06-17 eCollection Date: 2022-01-01 DOI:10.2147/HIV.S362459
Esubalew Woldeyes, Henok Fisseha, Hailu Abera Mulatu, Abiy Ephrem, Henok Benti, Mehari Wale Alem, Ahmed Ibrahim Ahmed
{"title":"Prevalence of Clinical Cardiovascular Disease Risk Factors Among HIV Infected Patients on Anti-Retroviral Treatment in a Tertiary Hospital in Ethiopia.","authors":"Esubalew Woldeyes,&nbsp;Henok Fisseha,&nbsp;Hailu Abera Mulatu,&nbsp;Abiy Ephrem,&nbsp;Henok Benti,&nbsp;Mehari Wale Alem,&nbsp;Ahmed Ibrahim Ahmed","doi":"10.2147/HIV.S362459","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anti-retroviral treatment has improved mortality of human immunodeficiency virus (HIV) infected patients, which is offset by an increasing burden of cardiovascular diseases (CVD). Data regarding prevalence of cardiovascular disease risk factors in HIV infected patients in Ethiopia are very scarce. The aim of this study was to determine the prevalence of CVD risks and associated factors in patients with HIV.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on 333 patients with HIV infection, using a modified World Health Organization's stepwise approach to surveillance questionnaire. Anthropometric and blood pressure measurement was done along with biochemical studies. Cardiovascular risk was estimated using Framingham risk score. Multivariate logistic regression was used to examine the association between cardiovascular risks and associated factors, with a p-value of <0.05 considered statistically significant.</p><p><strong>Results: </strong>The mean age of the participants was 45 years, and 69.2% were females. Most (80.9%) of the participants had viral load below 50 copies/mL and the mean CD4 count was 579 cells/mm<sup>3</sup>. Dyslipidemia was the most common risk factor identified in 69.4%, followed by abnormal fasting blood glucose (≥100 mg/dL) in 36.8%. Hypertension was diagnosed in 23.8%, while 22.8% and 11.1% had metabolic syndrome and obesity, respectively. Framingham risk score was low in 95.9%. Male gender, increasing age, high body mass index and previous ART regimen being tenofovir disoproxil fumarate, lamivudine and nevirapine increased CVD risk factors.</p><p><strong>Conclusion: </strong>Traditional cardiovascular risk factors were high in the population studied. There is a need to raise awareness about the risk factors, and patients should have timely follow-up and care.</p>","PeriodicalId":46555,"journal":{"name":"HIV AIDS-Research and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/f7/hiv-14-297.PMC9211102.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV AIDS-Research and Palliative Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HIV.S362459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 5

Abstract

Background: Anti-retroviral treatment has improved mortality of human immunodeficiency virus (HIV) infected patients, which is offset by an increasing burden of cardiovascular diseases (CVD). Data regarding prevalence of cardiovascular disease risk factors in HIV infected patients in Ethiopia are very scarce. The aim of this study was to determine the prevalence of CVD risks and associated factors in patients with HIV.

Methods: A cross-sectional study was conducted on 333 patients with HIV infection, using a modified World Health Organization's stepwise approach to surveillance questionnaire. Anthropometric and blood pressure measurement was done along with biochemical studies. Cardiovascular risk was estimated using Framingham risk score. Multivariate logistic regression was used to examine the association between cardiovascular risks and associated factors, with a p-value of <0.05 considered statistically significant.

Results: The mean age of the participants was 45 years, and 69.2% were females. Most (80.9%) of the participants had viral load below 50 copies/mL and the mean CD4 count was 579 cells/mm3. Dyslipidemia was the most common risk factor identified in 69.4%, followed by abnormal fasting blood glucose (≥100 mg/dL) in 36.8%. Hypertension was diagnosed in 23.8%, while 22.8% and 11.1% had metabolic syndrome and obesity, respectively. Framingham risk score was low in 95.9%. Male gender, increasing age, high body mass index and previous ART regimen being tenofovir disoproxil fumarate, lamivudine and nevirapine increased CVD risk factors.

Conclusion: Traditional cardiovascular risk factors were high in the population studied. There is a need to raise awareness about the risk factors, and patients should have timely follow-up and care.

埃塞俄比亚某三级医院接受抗逆转录病毒治疗的艾滋病毒感染者的临床心血管疾病危险因素患病率
背景:抗逆转录病毒治疗改善了人类免疫缺陷病毒(HIV)感染患者的死亡率,这被心血管疾病(CVD)负担的增加所抵消。关于埃塞俄比亚艾滋病毒感染者中心血管疾病风险因素流行率的数据非常少。本研究的目的是确定艾滋病毒感染者中心血管疾病风险的患病率及其相关因素。方法:采用改进的世界卫生组织逐步监测问卷法,对333例HIV感染者进行横断面研究。人体测量和血压测量与生化研究一起进行。使用Framingham风险评分评估心血管风险。多因素logistic回归分析心血管风险与相关因素的关系,p值为:参与者平均年龄45岁,女性69.2%。大多数(80.9%)参与者的病毒载量低于50拷贝/mL,平均CD4计数为579细胞/mm3。血脂异常是最常见的危险因素(69.4%),其次是空腹血糖异常(≥100 mg/dL)(36.8%)。23.8%的人被诊断为高血压,22.8%和11.1%的人分别被诊断为代谢综合征和肥胖。Framingham风险评分低,为95.9%。男性、年龄增长、高体重指数和以前的抗逆转录病毒治疗方案为富马酸替诺福韦、拉米夫定和奈韦拉平增加了心血管疾病的危险因素。结论:传统心血管危险因素在研究人群中较高。有必要提高对风险因素的认识,患者应得到及时的随访和护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
6.70%
发文量
61
审稿时长
16 weeks
期刊介绍: About Dove Medical Press Dove Medical Press Ltd is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC. We specialize in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Medical Press was founded in 2003 with the objective of combining the highest editorial standards with the ''best of breed'' new publishing technologies. We have offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and our editorial offices are in Auckland, New Zealand. Dr Scott Fraser is our Medical Director based in the UK. He has been in full time clinical practice for over 20 years as well as having an active research interest.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信